Drug name - Zykadia

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8835430 NOVARTIS 2,4-pyrimidinediamine compounds and their uses
Jan, 2023

(3 months from now)

US9018204 NOVARTIS 2,4-pyrimidinediamine compounds and their uses
Jan, 2023

(3 months from now)

US8188276 NOVARTIS 2,4-pyrimidinediamine compounds and their uses
Jan, 2023

(3 months from now)

US9416112 NOVARTIS 2,4-pyrimidinediamine compounds and their uses
Jan, 2023

(3 months from now)

US7893074 NOVARTIS 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
Apr, 2026

(3 years from now)

US8399450 NOVARTIS Compounds and compositions as protein kinase inhibitors
Nov, 2027

(5 years from now)

US7964592 NOVARTIS 2,4-di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
Apr, 2028

(5 years from now)

US8039479 NOVARTIS Compounds and compositions as protein kinase inhibitors
Jun, 2030

(7 years from now)

US9309229 NOVARTIS Crystalline forms of 5-chloro-N2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine
Jan, 2032

(9 years from now)

CN101514191A NOVARTIS Method Of Treating Or Preventing Autoimmune Diseases With 2,4-Pyrimidinediamine Compounds
Jun, 2011

(11 years ago)

CN102317268A NOVARTIS 2-Biphenylamion-4-Aminopyrimidine Derivatives As Kinase Inhibitors
Jul, 2014

(8 years ago)

CN101616895A NOVARTIS Compounds And Compositions As Protein Kinase Inhibitors
Sep, 2014

(8 years ago)

CN103282359A NOVARTIS 5-Chloro--N2-(2-Isopropoxy--5-Methyl--4-Piperidin--4-Yl-Phenyl)--N4-[2-(Propane--2-Sulfonyl)-Phenyl]--2, 4-Diamine In Crystalline Form.
Jun, 2017

(5 years ago)

CN104262324A NOVARTIS 5 - -N2-(2-Isopropoxy - -5 - Methyl - -4 - Piperidine - -4 - Yl-Phenyl)--N4-[2 - (Propane - -2 - Sulphonyl) - Phenyl]--2, 4-Diamine In Crystalline Form
Jul, 2017

(5 years ago)

CN107056751A NOVARTIS Crystalline Form Of Alk Inhibitor
Mar, 2021

(1 year, 6 months ago)

CN1625400B NOVARTIS 2, 4-Pyridine Diamine Compound And Application Thereof
Jan, 2023

(3 months from now)

CN1625400A NOVARTIS 2, 4-Pyrimidine Diamine Compound And Use Thereof
Jan, 2023

(3 months from now)

CN102174024B NOVARTIS 2, 4-Pyridine Diamine Compound And Application Thereof
Jan, 2023

(3 months from now)

CN102174024A NOVARTIS 2,4-Pyrimidinediamine Compounds And Application Thereof
Jan, 2023

(3 months from now)

CN103169708A NOVARTIS Methods Of Treating Or Preventing Autoimmune Diseases With 2,4-Pyrimidinediamine Compounds
Jul, 2023

(9 months from now)

CN103169708B NOVARTIS 2, 4-Pyrimidine Diamine Compound For Treating Or Preventing Autoimmune Disease In A Subject
Jul, 2023

(9 months from now)

CN1788001B NOVARTIS 2, 4- Di (Phenylamino) Pyrimidines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders
Mar, 2024

(1 year, 5 months from now)

CN101921236B NOVARTIS 2, 4- Di (Phenylamino) Pyrimidines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders
Mar, 2024

(1 year, 5 months from now)

CN101921236A NOVARTIS 2,4-Di(Phenylamino) Pyrimidines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders
Mar, 2024

(1 year, 5 months from now)

CN1788001A NOVARTIS Can Be Used For The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders For 2, 4-Di (Phenylamino) Pyrimidine
Mar, 2024

(1 year, 5 months from now)

CN1832929B NOVARTIS 2, 4-Thonzylamine For Treating Neoplasia Disease, Inflammation And The Immune System Disorder
Mar, 2024

(1 year, 5 months from now)

CN1832929A NOVARTIS For Treating Neoplastic Disease, Inflammation, And Diseases Of The Immune System Of 2, 4-Pyrimidine Diamine
Mar, 2024

(1 year, 5 months from now)

IN200401139P2 NOVARTIS 2,4-Pyrimidinediamine Compounds And Their Uses
Jan, 2023

(3 months from now)

IN239514B NOVARTIS 2,4 - Pyrimidinediamine Compounds And Their Uses
Jan, 2023

(3 months from now)

IN200502241P4 NOVARTIS 2,4-Di (Phenylamino) Pyrimidines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders
Mar, 2024

(1 year, 5 months from now)

IN232653B NOVARTIS 2,4-Di(Phenylamino)Pyrimidines For The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders
Mar, 2024

(1 year, 5 months from now)

IN200600553P4 NOVARTIS 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders
Aug, 2024

(1 year, 10 months from now)

IN240560B NOVARTIS 2,4-Pyrimidinediamines And A Pharmaceutical Composition Comprising The Same
Aug, 2024

(1 year, 10 months from now)

IN200903951P1 NOVARTIS Compounds And Compositions As Protein Kinase Inhibitors
Nov, 2027

(5 years from now)

IN276026B NOVARTIS Compounds And Compositions As Protein Kinase Inhibitors
Nov, 2027

(5 years from now)

EP2091918B1 NOVARTIS Compounds And Compositions As Protein Kinase Inhibitors
Jul, 2020

(2 years ago)

EP2091918A2 NOVARTIS Compounds And Compositions As Protein Kinase Inhibitors
Jul, 2020

(2 years ago)

EP2651918A1 NOVARTIS Crystalline Forms Of 5-Chloro-N2-(2-Isopropoxy-5-Methyl-4-Piperidin-4-Yl-Phenyl)-N4[2-(Propane-2-Sulfonyl)-Phenyl]-Pyrimidine-2,4-Diamine
Jun, 2022

(4 months ago)

EP2651918B1 NOVARTIS Crystalline Forms Of 5-Chloro-N2-(2-Isopropoxy-5-Methyl-4-Piperidin-4-Yl-Phenyl)-N4[2-(Propane-2-Sulfonyl)-Phenyl]-Pyrimidine-2,4-Diamine
Jun, 2022

(4 months ago)

EP2281563B1 NOVARTIS 2,4-Pyrimidinediamine Compounds And Their Uses
Jan, 2023

(3 months from now)

EP1471915A2 NOVARTIS 2,4-Pyrimidinediamine Compounds And Their Uses
Jan, 2023

(3 months from now)

EP2281563A1 NOVARTIS 2,4-Pyrimidinediamine Compounds And Their Uses
Jan, 2023

(3 months from now)

EP1471915A4 NOVARTIS 2,4-Pyrimidinediamine Compounds And Their Uses
Jan, 2023

(3 months from now)

EP1471915B1 NOVARTIS 2,4-Pyrimidinediamine Compounds And Their Uses
Jan, 2023

(3 months from now)

EP1534286B1 NOVARTIS Methods Of Treating Or Preventing Autoimmune Diseases With 2,4-Pyrimidinediamine Compounds
Jul, 2023

(9 months from now)

EP2316459B1 NOVARTIS 2,4-Pyrimidinediamine Compounds For Use In Methods Of Treating Or Preventing Autoimmune Diseases
Jul, 2023

(9 months from now)

EP2316459A1 NOVARTIS 2,4-Pyrimidinediamine Compounds For Use In Methods Of Treating Or Preventing Autoimmune Diseases
Jul, 2023

(9 months from now)

EP1534286A1 NOVARTIS Methods Of Treating Or Preventing Autoimmune Diseases With 2,4-Pyrimidinediamine Compounds
Jul, 2023

(9 months from now)

EP1606265A1 NOVARTIS 2, 4- Di (Phenylamino) Pyrimidines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders
Mar, 2024

(1 year, 5 months from now)

EP1606265B1 NOVARTIS 2, 4- Di (Phenylamino) Pyrimidines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders
Mar, 2024

(1 year, 5 months from now)

EP2275413B1 NOVARTIS 2,4-Di(Phenylamino)-Pyrimidines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders
Mar, 2024

(1 year, 5 months from now)

EP2275413A1 NOVARTIS 2,4-Di(Phenylamino)-Pyrimidines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders
Mar, 2024

(1 year, 5 months from now)

EP2287156A1 NOVARTIS 2,4-Di(Phenylamino)-Pyrimidines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders
Aug, 2024

(1 year, 10 months from now)

EP1660458A1 NOVARTIS 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders
Aug, 2024

(1 year, 10 months from now)

EP1660458B1 NOVARTIS 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders
Aug, 2024

(1 year, 10 months from now)

EP2287156B1 NOVARTIS 2,4-Di(Phenylamino)-Pyrimidines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders
Aug, 2024

(1 year, 10 months from now)

EP2311807B1 NOVARTIS Compounds And Composition As Protein Kinase Inhibitors
Nov, 2027

(5 years from now)

EP2311807A1 NOVARTIS Compounds And Composition As Protein Kinase Inhibitors
Nov, 2027

(5 years from now)

EP3121171B1 NOVARTIS Crystalline Forms Of 5-Chloro-N2-(2-Isopropoxy-5-Methyl-4-Piperidin-4-Yl-Phenyl)-N4[2-(Propane-2-Sulfonyl)-Phenyl]-Pyrimidine-2,4-Diamine
Dec, 2031

(9 years from now)

EP3453708B1 NOVARTIS Process For The Preparation Of 5-Chloro-N2-(2-Isopropoxy-5-Methyl-4-Piperidin-4-Yl-Phenyl)-N4-[2-(Propane-2-Sulfonyl)-Phenyl]-Pyrimidine-2, 4-Diamine Di-Hydrochloride
Dec, 2031

(9 years from now)

EP3121171A1 NOVARTIS Crystalline Forms Of 5-Chloro-N2-(2-Isopropoxy-5-Methyl-4-Piperidin-4-Yl-Phenyl)-N4[2-(Propane-2-Sulfonyl)-Phenyl]-Pyrimidine-2,4-Diamine
Dec, 2031

(9 years from now)

EP3453708A1 NOVARTIS Process For The Preparation Of 5-Chloro-N-(2-Isopropoxy-5-Methyl-4-Piperidin-4-Yl-Phenyl)-N-2-(Isopropylsulfonyl)Phenyl)-2,4-Diamine Di-Hydrochloride
Dec, 2031

(9 years from now)

EP3453708B8 NOVARTIS Process For The Preparation Of 5-Chloro-N2-(2-Isopropoxy-5-Methyl-4-Piperidin-4-Yl-Phenyl)-N4-[2-(Propane-2-Sulfonyl)-Phenyl]-Pyrimidine-2, 4-Diamine Di-Hydrochloride
Dec, 2031

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8377921 NOVARTIS Compounds and compositions as protein kinase inhibitors Nov, 2027

(5 years from now)

US8703787 NOVARTIS Methods of using ALK inhibitors Feb, 2032

(9 years from now)

Drugs and Companies using CERITINIB ingredient

Treatment: Treatment of a cancer mediated by an anaplastic lymphoma kinase (alk)

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
150MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.